A Randomized, Double-blind, Active-controlled, Multicenter Phase I Trial to Investigate the Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb
Latest Information Update: 30 Mar 2023
At a glance
- Drugs Botulinum toxin (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions
- Sponsors CKD Pharmaceuticals
Most Recent Events
- 27 Mar 2023 Status changed from not yet recruiting to completed.
- 24 May 2022 New trial record